Researchers hope to hijack a natural process called RNA interference to block the production of proteins linked to disease and treat medical conditions for which conventional drugs do not work, including cancer, heart disease, HIV and Parkinson’s disease.

In a new state-of-the-art lab at SLAC National Accelerator Laboratory, components of ribosomes – tiny biological machines that make new proteins and play a vital role in gene expression and antibiotic treatments – form crystals in a liquid solution.

A new screening program will allow researchers to quickly confirm whether precious biological samples yield useful information when struck by the intense X-ray pulses at SLAC's Linac Coherent Light Source (LCLS).

Last year's Nobel Prize in Chemistry – shared by Stanford School of Medicine Professor Brian Kobilka and Robert Lefkowitz of Duke University – recognized groundbreaking research in G protein-coupled receptors (GPCRs).

Daniel DePonte, a pioneer in finding ways to serve up a steady and precise supply of crystals, viruses and other precious samples for laser experiments, is the newly hired sample-delivery group leader for SLAC’s Linac Coherent Light Source X-ray laser.

X-rays Pinpoint Drug Target for Bacteria that Affect Hundreds of Millions Worldwide

Understanding why proteins interact with certain specific molecules and not with the myriad others in their environment is a major goal of molecular biology.

An international team led by the U.S. Department of Energy's (DOE) SLAC National Accelerator Laboratory has proved how the world's most powerful X-ray laser can assist in cracking the structures of biomolecules, and in the processes helped to pioneer critical...

Discovery paves the way for new synthesis of antibiotics